Investors Buy High Volume of Call Options on ALT5 Sigma (NASDAQ:ALTS)

ALT5 Sigma Corporation (NASDAQ:ALTS) saw unusually large options trading activity on Monday. Investors acquired 5,152 call options on the stock. This represents an increase of approximately 198% compared to the average volume of 1,727 call options.

ALT5 Sigma Stock Down 8.9%

Shares of ALTS stock opened at $1.12 on Tuesday. ALT5 Sigma has a 1 year low of $1.00 and a 1 year high of $10.95. The company has a debt-to-equity ratio of 0.01, a quick ratio of 0.79 and a current ratio of 0.79. The stock’s 50 day simple moving average is $1.60 and its two-hundred day simple moving average is $1.94.

ALT5 Sigma (NASDAQ:ALTS) last announced its earnings results on Monday, January 12th. The company reported $0.29 EPS for the quarter. The firm had revenue of $7.58 million during the quarter. ALT5 Sigma had a return on equity of 8.60% and a net margin of 133.06%.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of ALT5 Sigma in a research report on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company has an average rating of “Sell”.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Crcm LP raised its stake in shares of ALT5 Sigma by 373.2% in the fourth quarter. Crcm LP now owns 10,941,280 shares of the company’s stock valued at $12,035,000 after acquiring an additional 8,629,103 shares during the period. Vanguard Group Inc. boosted its stake in shares of ALT5 Sigma by 775.4% during the 3rd quarter. Vanguard Group Inc. now owns 6,126,395 shares of the company’s stock worth $16,480,000 after purchasing an additional 5,426,519 shares during the period. Prelude Capital Management LLC purchased a new position in shares of ALT5 Sigma during the 3rd quarter worth about $6,216,000. NWI Management LP bought a new position in ALT5 Sigma during the 3rd quarter valued at about $4,842,000. Finally, Alyeska Investment Group L.P. bought a new position in ALT5 Sigma during the 3rd quarter valued at about $4,697,000. Institutional investors own 6.27% of the company’s stock.

ALT5 Sigma Company Profile

ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties.